Vincent Cottin1, Luca Richeldi2, Ivan Rosas3, Maria Otaola4, Jin Woo Song5, Sara Tomassetti6, Marlies Wijsenbeek7, Manuela Schmitz8, Carl Coeck9, Susanne Stowasser10, Rozsa Schlenker-Herceg11, Martin Kolb12. 1. National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, University of Lyon, INRA, UMR754, Lyon, France. vincent.cottin@chu-lyon.fr. 2. Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3. Baylor College of Medicine, Houston, TX, USA. 4. Fundación Para El Estudio de Enfermedades Fibrosantes del Pulmón, Buenos Aires, Argentina. 5. Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 6. Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy. 7. Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands. 8. Mainanalytics GmbH, Sulzbach, Germany. 9. SCS Boehringer Ingelheim Comm.V., Brussels, Belgium. 10. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. 11. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 12. McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada.
Abstract
BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib. METHODS:Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression of ILD within the prior 24 months despite management in clinical practice, were randomized to receive nintedanib or placebo. Certain immunomodulatory therapies were restricted for the first 6 months. We analyzed post-hoc the rate of decline in forced vital capacity (FVC) over 52 weeks in subgroups by glucocorticoid use at baseline and in analyses excluding subjects or FVC measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies. RESULTS:Of 663 subjects, 361 (54.4%) were takingglucocorticoids at baseline (353 at a dose of ≤ 20 mg/day). In the placebo group, the adjusted rate of decline in FVC (mL/year) over 52 weeks was numerically greater in subjects taking than not taking glucocorticoids at baseline (- 206.4 [SE 20.2] vs - 165.8 [21.9]). The difference between the nintedanib and placebo groups was 133.3 (95% CI 76.6, 190.0) mL/year in subjects taking glucocorticoids at baseline and 76.1 (15.0, 137.2) mL/year in subjects who were not (interaction P = 0.18). The effect of nintedanib on reducing the rate of FVC decline in analyses excluding subjects or measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies was similar to the primary analysis. The adverse event profile of nintedanib was similar between subjects who did and did not use prohibited or restricted therapies at baseline or during treatment with trial drug. CONCLUSIONS: In patients with progressive fibrosing ILDs, the effect of nintedanib on reducing FVC decline was not influenced by the use of immunomodulatory therapies. Nintedanib can be used in combination with immunomodulatory therapies in patients with progressive fibrosing ILDs. Trial registration ClinicalTrials.gov, NCT02999178. Registered 21 December 2016, https://clinicaltrials.gov/ct2/show/NCT02999178.
RCT Entities:
BACKGROUND: In the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib. METHODS: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression of ILD within the prior 24 months despite management in clinical practice, were randomized to receive nintedanib or placebo. Certain immunomodulatory therapies were restricted for the first 6 months. We analyzed post-hoc the rate of decline in forced vital capacity (FVC) over 52 weeks in subgroups by glucocorticoid use at baseline and in analyses excluding subjects or FVC measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies. RESULTS: Of 663 subjects, 361 (54.4%) were taking glucocorticoids at baseline (353 at a dose of ≤ 20 mg/day). In the placebo group, the adjusted rate of decline in FVC (mL/year) over 52 weeks was numerically greater in subjects taking than not taking glucocorticoids at baseline (- 206.4 [SE 20.2] vs - 165.8 [21.9]). The difference between the nintedanib and placebo groups was 133.3 (95% CI 76.6, 190.0) mL/year in subjects taking glucocorticoids at baseline and 76.1 (15.0, 137.2) mL/year in subjects who were not (interaction P = 0.18). The effect of nintedanib on reducing the rate of FVC decline in analyses excluding subjects or measurements taken after initiation of restricted immunomodulatory or antifibrotic therapies was similar to the primary analysis. The adverse event profile of nintedanib was similar between subjects who did and did not use prohibited or restricted therapies at baseline or during treatment with trial drug. CONCLUSIONS: In patients with progressive fibrosing ILDs, the effect of nintedanib on reducing FVC decline was not influenced by the use of immunomodulatory therapies. Nintedanib can be used in combination with immunomodulatory therapies in patients with progressive fibrosing ILDs. Trial registration ClinicalTrials.gov, NCT02999178. Registered 21 December 2016, https://clinicaltrials.gov/ct2/show/NCT02999178.
Authors: Steven D Nathan; Victor F Tapson; Jean Elwing; Franz Rischard; Jinesh Mehta; Shelley Shapiro; Eric Shen; Chunqin Deng; Peter Smith; Aaron Waxman Journal: Am J Respir Crit Care Med Date: 2022-01-15 Impact factor: 21.405
Authors: Vincent Cottin; Fernando J Martinez; R Gisli Jenkins; John A Belperio; Hideya Kitamura; Maria Molina-Molina; Inga Tschoepe; Carl Coeck; Dirk Lievens; Ulrich Costabel Journal: Respir Res Date: 2022-04-07
Authors: Eric L Matteson; Clive Kelly; Jörg H W Distler; Anna-Maria Hoffmann-Vold; James R Seibold; Shikha Mittoo; Paul F Dellaripa; Martin Aringer; Janet Pope; Oliver Distler; Alexandra James; Rozsa Schlenker-Herceg; Susanne Stowasser; Manuel Quaresma; Kevin R Flaherty Journal: Arthritis Rheumatol Date: 2022-05-02 Impact factor: 15.483